The big observational study looked at almost 100,000 COVID-19 patients at 671 associations involving December 20, 2019, and April 14, 2020 however, it wasn’t a clinical trial.
Released in The Lancet, the study included 14,888 individuals who have been treated with hydroxychloroquine or chloroquine.
Hydroxychloroquine was much debated as a COVID-19 therapy because French physician Didier Raoult stated that he was treating patients in Marseille with all the medication as well as an antibiotic. He also published a small study with no control group in March.
The drug has been studied in many clinical trials internationally such as the World Health Organization’s Solidarity trial.
The new international analysis found no advantage in COVID-19 patients but rather an increased chance of heart issues and death.
Approximately 9 percent of patients died in the control group compared to approximately 16 percent of the taking chloroquine, ” the analysis stated.
The analysis also revealed a higher risk in patients treated with chloroquine or hydroxychloroquine and an antibiotic.
Approximately 22 percent of patients treated with chloroquine and an antibiotic expired and 23 percent of the taking hydroxychloroquine and an antibiotic expired, based on the analysis.
Chloroquine is a medication that’s existed since the 1940s to deal with malaria and hydroxychloroquine is a less toxic derivative of it has some significant unwanted effects such as nausea, headache, nausea, and in some instances heart issues.
US President Donald Trump had criticized that the drug’s usage against COVID-19 in mid-March, stating that it revealed”very quite encouraging early results”. He explained this month controversially he was carrying it as a precaution against coronavirus and he felt fine.
France’s health minister Olivier Véran tweeted an aide counsel would start looking in the usage of the medication following the launch of The Lancet research to reassess government advice around its usage.
Hype within the drug’s usage spurred global supply deficits which place patients with autoimmune ailments that rely upon the medication for therapy in danger.
“Our analysis has many limitations. The institution of decreased survival using hydroxychloroquine or chloroquine therapy regimens must be interpreted carefully,” because of the observational nature of this analysis, researchers said of this new worldwide study published Friday.
“It does give us a degree of assurance that we’re not likely to see significant benefits from these types of medications in treating COVID-19 and potentially injury,” Aronoff, that wasn’t involved in the study, told the AP.